Maher Masoud has bought MXCT on 2 days since Jun 2024

Masoud Maher (public filings and corporate materials list him as Maher Masoud) is a biopharmaceutical executive and President and Chief Executive Officer of MaxCyte, Inc. (NASDAQ/LSE: MXCT), a cell‑engineering company enabling the discovery, development and commercialization of next‑generation cell therapies.( A corporate insider at MaxCyte, he was appointed President and CEO effective January 1, 2024, after serving as the company’s Executive Vice President, Head of Global Business Development and Chief Counsel, and as Executive Vice President and General Counsel.( Across more than 25 years in the biopharmaceutical industry, including 17 years as an attorney and general counsel, he has helped expand MaxCyte’s strategic platform license partnerships and has contributed to three FDA‑approved therapies, Benlysta®, Vistogard® and Xuriden®.(

Maher began his career as a research associate at Glen Research (a Maravai company), then moved to Human Genome Sciences as director and corporate counsel, overseeing legal activities for global clinical trials until its acquisition by GlaxoSmithKline.( He later managed operations for six business subsidiaries at Wellstat, a life sciences holding company, and also served as co‑founding partner at the law firm RossiMasoud LLC before joining MaxCyte in 2017.( He holds a Bachelor of Science in cell and molecular biology genetics from the University of Maryland and a Juris Doctor from Michigan State University College of Law, combining scientific training with legal and business expertise in his leadership of MaxCyte.(

Written by Perplexity from public sources.